{"schema_version":"secwatch.filing_event.v1","accession":"0001110803-25-000014","form_type":"8-K","ticker":"ILMN","cik":"0001110803","company_name":"ILLUMINA, INC.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.954918+00:00","generated_at":"2026-05-27T01:24:58.920143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Illumina Q4 core revenue up 1% to $1.1B; FY2025 guided to low single-digit growth","bullets":["Core Illumina Q4 revenue $1.104B (+1% YoY); GAAP EPS $0.73, non-GAAP EPS $0.95.","Full year core revenue $4.332B (-2% YoY); free cash flow $1.07B.","FY2025 guidance: core revenue $4.28B-$4.4B; non-GAAP Op margin ~23%; non-GAAP EPS $4.50-$4.65.","China Ministry of Commerce impact excluded from guidance; company notes current macro/political environment.","Key partnerships announced: NVIDIA, UK Biobank proteomics, Regeneron/Truveta Genome Project."],"urls":{"canonical":"https://secwatch.observer/filing/0001110803-25-000014","json":"https://secwatch.observer/filing/0001110803-25-000014.json","markdown":"https://secwatch.observer/filing/0001110803-25-000014.md","text":"https://secwatch.observer/filing/0001110803-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1110803/000111080325000014/0001110803-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1110803/000111080325000014/ilmn-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:24:58.920143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}